Literature DB >> 22009965

Expression of b-FGF and endostatin and their clinical significance in human osteosarcoma.

Chao-Jian Xu1, Jie-Fu Song, Yun-Xing Su, Xiao-Li Liu.   

Abstract

OBJECTIVE: To investigate the expression and the clinical significance of basic fibroblast growth factor (b-FGF) and endostatin in osteosarcoma.
METHODS: From January 2003 to December 2005, expression of b-FGF, endostatin and CD34 were detected in 30 osteosarcoma and 30 osteochondroma tissue specimens by the immunohistochemical Elivision method. All data were post-processed with SPSS 13.0 software and prepared for investigation and analysis of these expressions and the relationships between the parameters.
RESULTS: (i) The rates of expression of b-FGF, endostatin and CD34 protein in osteosarcoma were 76.7%, 93.3%, and 96.7%, respectively, and in osteochondroma 43.3%, 40.0% and 16.7%, respectively. Each of the three expressions showed obvious differences between the osteosarcoma and the osteochondroma group. (ii) In the osteosarcoma group, expression of endostatin was positively correlated with that of CD34 (P < 0.05, γs = 0.528), and expression of endostatin in poorly differentiated osteosarcoma was much greater than that in highly differentiated osteosarcoma (P= 0.004). Expression of endostatin correlated with osteosarcoma metastasis (P= 0.036). (iii) There was no correlation between b-FGF and endostatin expression rates (P= 0.182) in the osteosarcoma group.
CONCLUSION: Angiogenesis is the basis of tumor metastasis, as well as being an important factor in tumor growth. Expression of endostatin could be adopted as a parameter for the diagnosis of postoperative metastases and for assessing prognosis, and could act as an adjuvant indicator in the grading of osteosarcoma.
© 2010 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22009965      PMCID: PMC6583316          DOI: 10.1111/j.1757-7861.2010.00102.x

Source DB:  PubMed          Journal:  Orthop Surg        ISSN: 1757-7853            Impact factor:   2.071


  4 in total

1.  Evaluating a Panel of Autoantibodies Against Tumor-Associated Antigens in Human Osteosarcoma.

Authors:  Manli Luo; Songmei Wu; Yan Ma; Hong Liang; Yage Luo; Wentao Gu; Lijuan Fan; Yang Hao; Haiting Li; Linbo Xing
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

2.  Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.

Authors:  Marie-Dominique Tabone; Laurence Brugières; Sophie Piperno-Neumann; Marie-Ange Selva; Perrine Marec-Bérard; Hélène Pacquement; Cyril Lervat; Nadège Corradini; Jean-Claude Gentet; Rémy Couderc; Aurélie Chevance; Céline Mahier-Ait Oukhatar; Natacha Entz-Werle; Jean-Yves Blay; Marie-Cecile Le Deley
Journal:  BMC Cancer       Date:  2017-06-15       Impact factor: 4.430

3.  Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.

Authors:  M Nyakas; E Aamdal; K D Jacobsen; T K Guren; S Aamdal; K T Hagene; P Brunsvig; A Yndestad; B Halvorsen; K A Tasken; P Aukrust; G M Maelandsmo; T Ueland
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

4.  Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.

Authors:  Anita K Luu; Mia Cadieux; Mackenzie Wong; Rachel Macdonald; Robert Jones; Dongsic Choi; Michelle Oblak; Brigitte Brisson; Scott Sauer; James Chafitz; David Warshawsky; Geoffrey A Wood; Alicia M Viloria-Petit
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.